Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 53,566 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider Lorenz Muller sold 53,566 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $124,273.12. Following the sale, the insider directly owned 196,486 shares in the company, valued at approximately $455,847.52. This trade represents a 21.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lorenz Muller also recently made the following trade(s):

• On Monday, January 26th, Lorenz Muller sold 11,180 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $1.93, for a total transaction of $21,577.40.

Milestone Pharmaceuticals Stock Performance

NASDAQ MIST opened at $1.94 on Thursday. The firm has a market cap of $165.23 million, a P/E ratio of -2.37 and a beta of 0.44. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The company’s 50 day moving average is $2.23 and its 200-day moving average is $1.96. Milestone Pharmaceuticals Inc. has a 12-month low of $0.63 and a 12-month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. Sell-side analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MIST. Simplify Asset Management Inc. raised its stake in Milestone Pharmaceuticals by 186.2% in the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after purchasing an additional 1,842,974 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after buying an additional 110,699 shares during the last quarter. Aptus Capital Advisors LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $420,000. Propel Bio Management LLC lifted its holdings in shares of Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Finally, Raymond James Financial Inc. grew its position in Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after acquiring an additional 10,000 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MIST shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Wells Fargo & Company raised their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Milestone Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.